Literature DB >> 30488488

Lymphotoxin-β receptor-NIK signaling induces alternative RELB/NF-κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer.

Rita Das1, Jamie Coupar1, Paul E Clavijo1, Anthony Saleh1, Tsu-Fan Cheng1, Xinping Yang1, Jianhong Chen1, Carter Van Waes1, Zhong Chen1.   

Abstract

Head and neck squamous cell carcinomas (HNSCC) preferentially spread to regional cervical tissues and lymph nodes. Here, we hypothesized that lymphotoxin-β (LTβ), receptor LTβR, and NF-κB-inducing kinase (NIK), promote the aberrant activation of alternative NF-κB2/RELB pathway and genes, that enhance migration and invasion of HNSCC. Genomic and expression alterations of the alternative NF-kB pathway were examined in 279 HNSCC tumors from The Cancer Genome Atlas (TCGA) and a panel of HNSCC lines. LTβR is amplified or overexpressed in HNSCC of the larynx or oral cavity, while LTβ, NIK, and RELB are overexpressed in cancers arising within lymphoid oropharyngeal and tonsillar sites. Similarly, subsets of HNSCC lines displayed overexpression of LTβR, NIK, and RELB proteins. Recombinant LTβ, and siRNA depletion of endogenous LTβR and NIK, modulated expression of LTβR, NIK, and nuclear translocation of NF-κB2(p52)/RELB as well as functional NF-κB promoter reporter activity. Treatment with a NIK inhibitor (1,3[2H,4H]-Iso-Quinoline Dione) reduced the protein expression of NIK and NF-κB2(p52)/RELB, and blocked LTβ induced nuclear translocation of RELB. NIK and RELB siRNA knockdown or NIK inhibitor slowed HNSCC migration or invation in vitro. LTβ-induces expression of migration and metastasis related genes, including hepatocyte growth/scatter factor receptor MET. Knockdown of NIK or MET similarly inhibited the migration of HNSCC cell lines. This may help explain why HNSCC preferentially migrate to local lymph nodes, where LTβ is expressed. Our findings show that LTβ/LTβR promotes activation of the alternative NIK-NF-κB2/RELB pathway to enhance MET-mediated cell migration in HNSCC, which could be potential therapeutic targets in HNSCC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  HNSCC; LTβ/LTβ receptor; NIK; RELB/NF-κB2; migration

Mesh:

Substances:

Year:  2018        PMID: 30488488      PMCID: PMC7066987          DOI: 10.1002/mc.22938

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  51 in total

1.  ΔNp63 versatilely regulates a Broad NF-κB gene program and promotes squamous epithelial proliferation, migration, and inflammation.

Authors:  Xinping Yang; Hai Lu; Bin Yan; Rose-Anne Romano; Yansong Bian; Jay Friedman; Praveen Duggal; Clint Allen; Ryan Chuang; Reza Ehsanian; Han Si; Satrajit Sinha; Carter Van Waes; Zhong Chen
Journal:  Cancer Res       Date:  2011-05-15       Impact factor: 12.701

Review 2.  NF-κB and the link between inflammation and cancer.

Authors:  Joseph A DiDonato; Frank Mercurio; Michael Karin
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

3.  Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.

Authors:  G Dong; Z Chen; Z Y Li; N T Yeh; C C Bancroft; C Van Waes
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

4.  A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma.

Authors:  Colleen H Druzgal; Zhong Chen; Ning T Yeh; Giovana R Thomas; Frank G Ondrey; Dianne C Duffey; Ronald J Vilela; Kevin Ende; Linda McCullagh; Susan F Rudy; Christine Muir; Laurie L Herscher; John C Morris; Paul S Albert; Carter Van Waes
Journal:  Head Neck       Date:  2005-09       Impact factor: 3.147

Review 5.  Non-canonical NF-κB signaling pathway.

Authors:  Shao-Cong Sun
Journal:  Cell Res       Date:  2010-12-21       Impact factor: 25.617

Review 6.  Biology and signal transduction pathways of the Lymphotoxin-αβ/LTβR system.

Authors:  Caroline Remouchamps; Layla Boutaffala; Corinne Ganeff; Emmanuel Dejardin
Journal:  Cytokine Growth Factor Rev       Date:  2011 Oct-Dec       Impact factor: 7.638

Review 7.  The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development.

Authors:  M J Wolf; G M Seleznik; N Zeller; M Heikenwalder
Journal:  Oncogene       Date:  2010-07-05       Impact factor: 9.867

8.  NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176.

Authors:  L Ling; Z Cao; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

9.  Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.

Authors:  Clint Allen; Kunal Saigal; Liesl Nottingham; Pattatheyil Arun; Zhong Chen; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

10.  Induction of the alternative NF-κB pathway by lymphotoxin αβ (LTαβ) relies on internalization of LTβ receptor.

Authors:  Corinne Ganeff; Caroline Remouchamps; Layla Boutaffala; Cécile Benezech; Géraldine Galopin; Sarah Vandepaer; Fabrice Bouillenne; Sandra Ormenese; Alain Chariot; Pascal Schneider; Jorge Caamaño; Jacques Piette; Emmanuel Dejardin
Journal:  Mol Cell Biol       Date:  2011-09-06       Impact factor: 4.272

View more
  6 in total

1.  Head and Neck Cancers Promote an Inflammatory Transcriptome through Coactivation of Classic and Alternative NF-κB Pathways.

Authors:  Xinping Yang; Hui Cheng; Jianhong Chen; Ru Wang; Anthony Saleh; Han Si; Steven Lee; Emine Guven-Maiorov; Ozlem Keskin; Attila Gursoy; Ruth Nussinov; Jugao Fang; Carter Van Waes; Zhong Chen
Journal:  Cancer Immunol Res       Date:  2019-10-17       Impact factor: 11.151

2.  E3 ligase c-Cbl regulates intestinal inflammation through suppressing fungi-induced noncanonical NF-κB activation.

Authors:  Jie-Lin Duan; Hui-Qian He; Yao Yu; Tao Liu; Shu-Jun Ma; Fan Li; Yan-Shan Jiang; Xin Lin; De-Dong Li; Quan-Zhen Lv; Hui-Hui Ma; Xin-Ming Jia
Journal:  Sci Adv       Date:  2021-05-07       Impact factor: 14.136

3.  The decreased mean platelet volume is associated with poor prognosis in patients with oropharyngeal cancer treated with radiotherapy.

Authors:  Daniela Delago; Olivia Knittelfelder; Gabriele Jakse; Katarzyna Lukasiak; Sabine Reinisch; Wilfried Renner; Heidi Stranzl-Lawatsch; Richard Partl; Tanja Langsenlehner
Journal:  Radiat Oncol       Date:  2020-11-07       Impact factor: 3.481

4.  Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.

Authors:  Adrián Mosquera Orgueira; Roi Ferreiro Ferro; José Ángel Díaz Arias; Carlos Aliste Santos; Beatriz Antelo Rodríguez; Laura Bao Pérez; Natalia Alonso Vence; Ággeles Bendaña López; Aitor Abuin Blanco; Paula Melero Valentín; And Res Peleteiro Raindo; Miguel Cid López; Manuel Mateo Pérez Encinas; Marta Sonia González Pérez; Máximo Francisco Fraga Rodríguez; José Luis Bello López
Journal:  PLoS One       Date:  2021-05-04       Impact factor: 3.240

5.  Single-cell RNA Seq reveals cellular landscape-specific characteristics and potential etiologies for adolescent idiopathic scoliosis.

Authors:  Yilin Yang; Mingyuan Yang; Dongliang Shi; Kai Chen; Jian Zhao; Shisheng He; Yushu Bai; Pinquan Shen; Haijian Ni
Journal:  JOR Spine       Date:  2021-12-08

6.  Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival.

Authors:  Marij J P Welters; Noel F C C de Miranda; Ziena Abdulrahman; Saskia J Santegoets; Gregor Sturm; Pornpimol Charoentong; Marieke E Ijsselsteijn; Antonios Somarakis; Thomas Höllt; Francesca Finotello; Zlatko Trajanoski; Sylvia L van Egmond; Dana A M Mustafa; Sjoerd H van der Burg
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.